Drugs / gp120
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00001019 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2013-04-05 | Bionor Immuno AS | Results Bionor Pharma`s Hypothesis for Immune Activation Mediated by the C5 Region of HIV Presented at Scientific Conference bionorholding.com ↗
The C5 region of HIV-1 gp120 shares homology with the shared epitope of HLA-DRß1 and activates immune responses. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-10-23 | Clover Biopharmaceuticals AUS Pty | Clover initiated gp120-Trimer (SCB-703) AIDS vaccine study cloverbiopharma.com ↗ |
| 2013-04-05 | Bionor Immuno AS | Bionor Pharma`s Hypothesis for Immune Activation Mediated by the C5 Region of HIV Presented at Scientific Conference bionorholding.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001019 ↗ |
| Known as | SF-2 gp120 | “Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant” NCT00001019 ↗ |
| Modality | Vaccine | “One experimental AIDS vaccine is the gp120 vaccine.” NCT00001019 ↗ |